

Company	Trade Name	Generic Name	Action
Gilead Sciences Inc.	Truvada	emtricitabine and tenofovir disoproxil fumarate	The FDA has granted approval for Gilead Sciences' once-daily HIV medication, Truvada.
GlaxoSmithKline	Flovent HFA	fluticasone propionate HFA	The FDA has approved the use of GlaxoSmithKline's Flovent HFA inhalation aerosol in children 4 to 11 years of age with asthma.
GlaxoSmithKline	Relenza	zanamivir	The FDA has approved the use of Relenza for the prevention or prophylaxis of influenza in adults, and in children five years of age or older. Relenza, made by GlaxoSmithKline, is the second drug approved for prevention of flu, after Tamiflu.
Hanford Pharmaceuticals Inc.	Cefazolin	cephalosporin	An injectable antibiotic used in hospitals to treat skin and respiratory infections has been recalled because contaminants were found in the ingredient used to manufacture the product, according to drugmaker Hanford Pharmaceuticals Inc. The FDA alerted doctors and hospitals about contaminated lots of Cefazolin in a safety alert issued March 1. Four lots of Cefazolin are affected by the nationwide recall: lot numbers C4650 and C4537, distributed by Sandoz Inc.; and C4689 and C4665, distributed by Watson Pharmaceuticals Inc.
Impax Laboratories Inc.	Vadova	carbidopa levodopa	Impax Laboratories Inc. has received a nonapprovable letter from the FDA concerning the new drug application for Vadova tablets, a Parkinson's treatment. Impax will work with the agency and contract lab to provide additional data needed for approval.
Inspire Pharmaceuticals Inc.		diquafosol	Inspire Pharmaceuticals Inc. plans to provide additional information to the FDA regarding diquafosol, the company's dry eye treatment. Inspire and officials at the FDA recently met to discuss a December 2005 letter from the agency stating that diquafosol is approvable.
Medicis Pharmaceutical Corp.	Vanos	primezone	The FDA has approved a new use for the prescription skin cream Vanos, allowing it to be used to treat severely itchy or inflammatory skin conditions in youth and adults, drugmaker Medicis Pharmaceutical Corp. said.
Myogen Inc.		ambrisentan	The FDA has granted fast-track designation to ambrisentan, Myogen's investigational drug intended to treat pulmonary arterial hypertension.
NPS Pharmaceuticals Inc.	Preos	recombinant human parathyroid hormone	NPS Pharmaceuticals Inc. said that the FDA has determined the company's new drug application for Preos, an injectable drug intended to reduce fractures, is approvable.
Salix Pharmaceuticals Ltd.	OsmoPrep	sodium phosphate	The FDA has approved OsmoPrep, a colon-cleansing pill, for patients undergoing colonoscopy, according to Salix Pharmaceuticals Ltd.
Sanofi-Aventis	Taxotere Injection Concentrate	docetaxel	Sanofi-Aventis announced that the FDA has approved Taxotere Injection Concentrate, a drug for treatment of advanced stomach cancer. The approval is for use in combination with cisplatin and 5-fluorouracil for the treatment of patients with advanced stomach cancer, including cancer of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.